Docstoc

Global Diabetes Market Trends & Future Forecast – Diabetes Drug (Anti-Diabetic Drug), Insulin, DPP-IV, GLP-1

Document Sample
Global Diabetes Market Trends & Future Forecast – Diabetes Drug (Anti-Diabetic Drug), Insulin, DPP-IV, GLP-1 Powered By Docstoc
					Publisher: Renub Research
Published: June 2010
Report Details

“Global Diabetes Market Trends & Future Forecast – Diabetes Drug (Anti-Diabetic Drug),
Insulin, DPP-IV, GLP-1” report published by Renub Research provides an in-depth analysis of
the past, present and future prospects. The report has been researched at source globally,
country specific and features latest available data covering:


      Global Diabetes Drug, Insulin, DPP-IV, GLP-1 Agonists Market and Future Forecast
      Region wise Diabetes, Impaired Glucose Tolerance (IGT) Population and Prevalence
      Region wise Diabetes Health Expenditure and Mortality
      Top 10 Countries Diabetes Population and Future Forecast
      Top 5 Countries Diabetes Drug Market and Future Forecast
      Top 7 Countries Insulin Market and Future Forecast
      Top 6 Diabetes Drug Brands ( Avandia, Actos, Amaryl, Avandamet, Prandin/Novonorm,
       Starlix) data of Past, Present and Future Market
      Top 9 Insulin Brands (Novomix, Novorapid, Levemir, Degludec, Degludecplus, Humalog,
       Humulin, Apidra, Lantus) data of Past, Present and Future Market
      Top 4 DPP-IV Inhibitors (Januvia, Onglyza, Alogliptin, Galvus) data of Past,
       Present and Future Market
      Top 5 GLP-1 Agonists (Byetta, Victoza, Exenatide LAR, Syncria, Taspoglutide) data of
       Past, Present and Future Market


Research Highlights

      USA controls more than 50% of the total Diabetes Drug market share in 2009
      Global Insulin Market is estimated to reach around US$ 17 Billion by 2013
      China will have the second highest Insulin market share by 2012 replacing Germany
      DPP-IV Inhibitors is predicted to be more than US$ 5 Billion market by 2015
      GLP-1 Agonists, market is forecasted to cross US$ 6 Billion mark by 2015
      Novorapid is the blockbuster Insulin of Novo Nordisk it is expected to cross US$ 3
       Billion by 2015.




© Renub Research                          Page 2 of 18
        Yet to launched Degludec and DegludecPlus is expected to be blockbuster Insulin and
         cross US$ 4 Billion and US$ 6 Billion respectively by 2030.
        Januvia is proving a blockbuster of DPP – IV Inhibitors segment expected to be more
         than US$ 4 Billion by 2017
        Last year launched Victoza and yet to be launched Exenatide LAR is going to be
         blockbuster GLP-1 Agonists
        China diabetes drug market has crossed the figure of Yuan 10 Billion by 2009
        Japan Insulin market is expected to be more than US$ 1 Billion by 2010


Key Drugs Analyzed


Diabetes Drug: Avandia, Actos, Amaryl, Avandamet, Prandin/Novonorm, Starlix
Insulin: Novomix, Novorapid, Levemir, Degludec, Degludecplus, Humalog, Humulin, Apidra,
Lantus
DPP-IV Inhibitors: Januvia, Onglyza, Alogliptin, Galvus,
GLP-1 Agonists: Byetta, Victoza, Exenatide LAR, Syncria, Taspoglutide


Data Sources


Information and data in this report has been collected from various printable and non-
printable sources like Trade Journals, White papers, Online paid databases, News websites,
Government Agencies, Magazines, Newspapers and Trade associations.




© Renub Research                            Page 3 of 18
                                           Published By


                                      Renub Research
                                         A–116B, Sector–27
                                           Noida – 201301
                             Phone: +91-120-421-9822, 424-9780 (India)
                                       +1-678-302-0700 (US)
                                       Email: info@renub.com
                                          www.renub.com




© Global Diabetes Market Trends & Future Forecast – Diabetes Drug (Anti-Diabetic Drug), Insulin, DPP-
                                              IV, GLP-1
                                       Renub Research, 2010
                                             Edition 1.0
                          All rights reserved. This publication is protected
                       by copyright. No part of it may be reproduced, stored
                       in a retrieval system or transmitted, in any form or by
                         any means, electronic mechanical, photocopying,
                          recording or otherwise without the prior written
                                    permission of the publishers.




© Renub Research                            Page 4 of 18
                                          Table of Contents

1.     Executive Summary

2.     Global Diabetes Market

     2.1    Global – Diabetes Drug Market & Future Forecast

     2.2    Global – Insulin Market & Future Forecast

     2.3    Global – Diabetes Drug Market Share & Future Forecast of (Brazil, China, Japan, USA, India)

     2.4    Global – Insulin Market Share & Future Forecast of (Mexico, Germany, Russia, China, Japan,
     USA, India)

     2.5    Global – Dipeptidyl Peptidase (DPP – IV) Inhibitors Market & Future Forecast

     2.6    Global – Glucagon-like Peptide-1(GLP-1) Market & Future Forecast

3.     Global – Top 6 Diabetes Drug Brands Market Performance

     3.1    Avandia – Past & Present Market

     3.2    Actos – Past, Present & Future Forecast

     3.3    Amaryl – Past, Present & Future Forecast

     3.4    Avandamet – Past, Present & Future Forecast

     3.5    Prandin/Novonorm – Past & Present Market

     3.6    Starlix – Past, Present & Future Forecast

4.     Global – Top 9 Insulin Brands Market Performance

     4.1    Novomix – Past, Present & Future Forecast

     4.2    Novorapid – Past, Present & Future Forecast

     4.3    Levemir – Past, Present & Future Forecast

     4.4    Degludec – Yet to be Launched - Future Forecast

     4.5    Degludecplus – Yet to be Launched – Future Forecast

     4.6    Humalog – Past & Present Market

     4.7    Humulin – Past & Present Market

     4.8    Apidra – Past, Present & Future Forecast

     4.9    Lantus – Past, Present & Future Forecast



© Renub Research                                Page 5 of 18
5.     Global – DPP-IV Inhibitors Brands Market Performance

     5.1   Januvia – Past, Present & Future Forecast

     5.2   Onglyza – Past, Present & Future Forecast

     5.3   Alogliptin – Yet to be Launched – Future Forecast

     5.4   Galvus – Past, Present & Future Forecast

     5.5   DPP-IV Inhibitors – In Trial Phases

6.     Global – GLP-1 Agonists Brands Market Performance

     6.1   Byetta – Past, Present & Future Forecast

     6.2   Victoza – Past, Present & Future Forecast

     6.3   Exenatide LAR – Yet to be Launched – Future Forecast

     6.4   Syncria – Yet to be Launched – Future Forecast

     6.5   Taspoglutide – Yet to be Launched – Future Forecast

7.     Regional Estimates for Diabetes

     7.1   Diabetes – Population & Prevalence

     7.2   Impaired Glucose Tolerance (IGT) – Population & Prevalence

     7.3   Mortality – Due to Diabetes

     7.4   North America & Caribbean Region
       7.4.1   Diabetes & Impaired Glucose Tolerance (IGT) – Population & Prevalence
       7.4.2   Healthcare Expenditure & Type 1 Diabetes
       7.4.3   Mortality

     7.5   Middle East and North African Region
       7.5.1   Diabetes & Impaired Glucose Tolerance (IGT) – Population & Prevalence
       7.5.2   Healthcare Expenditure & Type 1 Diabetes
       7.5.3   Mortality

     7.6   South-East Asian Region
       7.6.1   Diabetes & Impaired Glucose Tolerance (IGT) – Population & Prevalence
       7.6.2   Healthcare Expenditure & Type 1 Diabetes
       7.6.3   Mortality

     7.7   European Region
       7.7.1   Diabetes & Impaired Glucose Tolerance (IGT) – Population & Prevalence
       7.7.2   Healthcare Expenditures & Type 1 Diabetes


© Renub Research                                 Page 6 of 18
       7.7.3        Mortality

     7.8    South and Central American Region
       7.8.1        Diabetes & Impaired Glucose Tolerance (IGT) – Population & Prevalence
       7.8.2        Healthcare Expenditures & Type 1 Diabetes
       7.8.3        Mortality

     7.9    Western Pacific Region
       7.9.1        Diabetes & Impaired Glucose Tolerance (IGT) – Population & Prevalence
       7.9.2        Healthcare Expenditures & Type 1 Diabetes
       7.9.3        Mortality

     7.10   African Region
       7.10.1       Diabetes & Impaired Glucose Tolerance (IGT) – Population & Prevalence
       7.10.2       Healthcare Expenditure & Type 1 Diabetes
       7.10.3       Mortality

8.     Global – Top 10 Diabetic Countries Performance

     8.1    Number of People in Top 10 Diabetic Place

     8.2    Prevalence of Diabetes in Top 10 Countries

     8.3    India
       8.3.1        Diabetes Population & Future Scenario
       8.3.2        India – Diabetes Drug Market & Future Forecast
       8.3.3        India-Insulin Market & Future Forecast

     8.4    China
       8.4.1        Diabetes Population & Future Scenario
       8.4.2        Diabetes Drug Market & Future Forecast
       8.4.3        China Insulin Market & Future Forecast

     8.5    United States
       8.5.1        Diabetes Population & Future Scenario
       8.5.2        Diabetes Drug Market & Future Forecast
       8.5.3        Insulin Market & Future Forecast

     8.6    Brazil
       8.6.1        Diabetes Population & Future Scenario
       8.6.2        Diabetes Drug Market & Future Forecast

     8.7    Russia
       8.7.1        Diabetes Population & Future Scenario
       8.7.2        Insulin Market & Future Forecast


© Renub Research                                   Page 7 of 18
  8.8    Japan
    8.8.1    Diabetes Population & Future Scenario
    8.8.2    Diabetes Drug Market & Future Forecast
    8.8.3    Insulin Market & Future Forecast

  8.9    Germany
    8.9.1    Diabetes Population & Future Scenario
    8.9.2    Insulin Market & Future Forecast

  8.10   Mexico
    8.10.1   Diabetes Population & Future Scenario
    8.10.2   Insulin Market & Future Forecast

  8.11   Indonesia
    8.11.1   Diabetes Population & Future Scenario

  8.12   Pakistan
    8.12.1   Diabetes Population & Future Scenario




© Renub Research                           Page 8 of 18
List of Figures:


Figure 2-1: Global – Diabetes Drug Market (Billion US$), 2005 – 2009
Figure 2-2: Global – Forecast of Diabetes Drug Market (Billion US$), 2010 – 2013
Figure 2-3: Global – Insulin Market (Billion US$), 2004 – 2009
Figure 2-4: Global – Forecast of Insulin Market (Billion US$), 2010 – 2013
Figure 2-5: Global – Diabetes Drug Market Share of (Brazil, China, Japan, USA, India) (Percent), 2007 –
     2009
Figure 2-6: Global – Forecast of Diabetes Drug Market Share of (Brazil, China, Japan, USA, India)
     (Percent), 2010 – 2013
Figure 2-7: Global – Insulin Market Share of (Mexico, Germany, Russia, China, Japan, USA, India)
     (Percent), 2007 – 2009
Figure 2-8: Global – Forecast for Insulin Market Share of (Mexico, Germany, Russia, China, Japan, USA,
     India) (Percent), 2010 – 2013
Figure 2-9: Global – DPP – IV Inhibitors Market (Million US$), 2009 – 2015
Figure 2-10: Global – GLP-1 Market (Million US$), 2009 – 2015
Figure 3-1: Global – Avandia Diabetes Drug Brand Sales (Million US$), 2004 – 2009
Figure 3-2: Global – Actos Diabetes Drug Sales (Billion US$), 2005 – 2009
Figure 3-3: Global – Forecast for Actos Diabetes Drug Sales (Billion US$), 2010 & 2013
Figure 3-4: Global – Amaryl Diabetes Drug Sales (Million US$), 2006, 2007, 2009, & Q1 2010
Figure 3-5: Global – Forecast for Amaryl Diabetes Drug Sales (Million US$), 2010 – 2012
Figure 3-6: Global – Avandamet Diabetes Drug Sales (Million US$), 2006 – 2009
Figure 3-7: Global – Forecast for Avandamet Diabetes Drug Sales (Million US$), 2010 – 2012
Figure 3-8: Global – Prandin/Novonorm Diabetes Drug Sales (Million US$), 2007 – 2009
Figure 3-9: Global – Starlix Diabetes Drug Sales (Million US$), 2007 – 2009E
Figure 3-10: Global – Forecast for Starlix Diabetes Drug Sales (Million US$), 2010 – 2012
Figure 4-1: Global – NovoMix Insulin Sales (Million US$), 2005 – 2009
Figure 4-2: Global – NovoRapid Insulin Sales (Million US$), 2005 – 2009
Figure 4-3: Global – Levemir Insulin Sales (Million US$), 2005 – 2009
Figure 4-4: Global – Humalog Insulin Sales (Million US$), 2006 – 2009
Figure 4-5: Global – Humulin Insulin Brand Sales (Million US$), 2006 – 2009
Figure 4-6: Global – Apidra Insulin Sales (Million US$), 2005 – 2009, Q1 2010
Figure 4-7: Apidra – Forecast for Insulin Sales (Million US$), 2009 – 2013
Figure 4-8: Global – Lantus Insulin Sales (Million US$), 2006 – 2009, Q1 2010
Figure 4-9: Global – Forecast for Lantus Insulin Sales (Million US$), 2010 – 2015
Figure 5-1: Global – Januvia DPP-IV Inhibitors Sales (Million US$), 2007 – 2009
Figure 5-2: Global – Forecast for Januvia DPP-IV Inhibitors Sales (Million US$), 2010 – 2017



© Renub Research                              Page 9 of 18
Figure 5-3: Global – Onglyza DPP-IV Inhibitors Sales & Future Forecast (Million US$), 2009 – 2017
Figure 5-4: Global – Future Forecast for Alogliptin DPP-IV Inhibitors Sale (Million US$), 2011 – 2017
Figure 5-5: Global – Galvus DPP-IV Inhibitors Sale (Million US$), 2007 – 2009
Figure 5-6: Global – Future Forecast for Galvus DPP-IV Inhibitors Sale (Million US$), 2010 – 2012
Figure 6-1: Global – Byetta GLP-1 Sales (Million US$), 2006 – 2009
Figure 6-2: Global – Forecast for Byetta GLP-1 Sales (Million US$), 2010 – 2017
Figure 6-3: Global – Victoza GLP-1 Sales & Future Forecast (Million US$), 2009 – 2017
Figure 6-4: Global – Forecast for Exenatide LAR GLP-1 Sales (Million US$), 2011 – 2017
Figure 6-5: Global – Forecast for Syncria GLP-1 Sales (Million US$), 2013 – 2017
Figure 6-6: Global – Forecast for Taspoglutide GLP-1 Sales (Million US$), 2012 – 2017
Figure 8-1: India – Number of People with Diabetes (Million), 2003, 2007, 2010
Figure 8-2: India – Diabetes Drug Market (Billion INR), 2006 – 2009
Figure 8-3: India – Forecast for Diabetes Drug Market (Billion INR), 2010 – 2014
Figure 8-4: India – Share of Human Insulin Market, Animal Insulin Market & Oral Diabetes Market (in
     Percent), 2003 & 2007
Figure 8-5: India – Insulin Market (Million INR), 2006 – 2009
Figure 8-6: India – Forecast for Insulin Market (Million INR), 2010 – 2014
Figure 8-7: China – Number of Diabetes Patients (Million), 2003, 2007 & 2010
Figure 8-8: China – Diabetes Drug Market (Billion Yuan), 2006 – 2009E
Figure 8-9: China – Forecast for Diabetes Drug Market (Billion Yuan) 2010 – 2014
Figure 8-10: China – Insulin Market (Million Yuan), 2007 – 2009
Figure 8-11: China – Forecast for Insulin Market (Million Yuan), 2010 – 2014
Figure 8-12: USA – Number of Diabetes Patients (Million), 2003, 2006, 2007 & 2010
Figure 8-13: USA – Diabetes Drug Market (Million US$), 2002 – 2009
Figure 8-14: USA – Forecast for Diabetes Drug Market (Million US$), 2010 – 2014
Figure 8-15: USA – Insulin Market (Billion US$), 2003 – 2009
Figure 8-16: USA – Forecast for Insulin Market (Billion US$), 2010 – 2014
Figure 8-17: Brazil – Diabetes Population (Million), 2003, 2007 & 2010
Figure 8-18: Brazil – Diabetes Drug Market (Million US$), 2008 – 2013
Figure 8-19: Russia – Number of Diabetes Population (Million), 2005 & 2010
Figure 8-20: Russia – Insulin Market (Million US$), 2002, 2005 – 2009
Figure 8-21: Russia – Forecast for Insulin Market (Million US$), 2010 – 2014
Figure 8-22: Japan – Number of Diabetes Population (Million), 2003 – 2010
Figure 8-23: Japan – Diabetes Drug Market (Million US$), 2002 – 2009
Figure 8-24: Japan – Forecast for Diabetes Market (Million US$), 2010 – 2014
Figure 8-25: Japan – Insulin Market (Million US$), 1998 – 2009
Figure 8-26: Japan – Forecast for Insulin Market (Million US$), 2010 – 2014



© Renub Research                               Page 10 of 18
Figure 8-27: Germany – Number of Diabetes Patients (Million), 2003 – 2010
Figure 8-28: Germany – Insulin Market (Million US$), 2004 – 2009E
Figure 8-29: Germany – Forecast for Insulin Market (Billion US$), 2010 – 2014
Figure 8-30: Mexico – Number of People with Diabetes (Million), 2003 – 2005, 2007 & 2010
Figure 8-31: Mexico – Insulin Market (Million US$), 2004 – 2009E
Figure 8-32: Mexico – Forecast for Insulin Market (Million US$), 2010 – 2014
Figure 8-33: Pakistan – Number of Diabetes Patients (Million), 2003, 2007 & 2010




© Renub Research                              Page 11 of 18
List of Tables:


Table 4-1: Novomix – Forecast for Insulin Sales (Million US$), 2010 – 2030
Table 4-2: Global – Forecast for NovoRapid Insulin Sales (Million US$), 2010 – 2030
Table 4-3: Global – Forecast for Levemir Insulin Sales (Million US$), 2010 – 2030
Table 4-4: Degludec – Forecast for Insulin Sales (Million US$), 2010 – 2030
Table 4-5: DegludecPlus – Forecast for Insulin Sales (Million US$), 2010 – 2030
Table 5-1: DPP-4 Inhibitors –In Trial Phase
Table 7-1: Regional – Estimates for (Number of People with Diabetes, Comparative Diabetes Prevalence
     %) (20-79 years), 2010 and 2030
Table 7-2: Regional – Estimates for (Number of People with IGT, Comparative IGT Prevalence %) (20-79
     years), 2010 and 2030
Table 7-3: Regional – Diabetes Mortality (20-79 Years; Thousand), 2010
Table 7-4: North America and Caribbean Region – Population & Adult Population (Million), 2010 & 2030
Table 7-5: North America and Caribbean Region – Number of People with Diabetes & Comparative
     Prevalence Percent (20-79 Years; Million, Percent), 2010 & 2030
Table 7-6: North America and Caribbean Region – Number of People with IGT & Comparative
     Prevalence Percent (20-79 Years; Million, Percent), 2010 & 2030
Table 7-7: North America and Caribbean Region – Health Expenditure for Diabetes (Billion) & Type 1
     Diabetes (0-14 Years; Thousand), 2010 & 2030
Table 7-8: North America and Caribbean Region – Diabetes Mortality (20-79 Years; Thousand), 2010
Table 7-9: Middle East and North African Region – Population & Adult Population (Million), 2010 & 2030
Table 7-10: Middle East and North African Region – Number of People with Diabetes & Comparative
     Prevalence (20-79 Years; Million, Percent), 2010 & 2030
Table 7-11: Middle East and North African Region – Number of People with IGT & Comparative
     Prevalence (20-79 Years; Million, Percent), 2010 & 2030
Table 7-12: Middle East and North African Region – Health Expenditure for Diabetes (Billion) & Type 1
     Diabetes (0-14 Years; Thousand), 2010 & 2030
Table 7-13: Middle East and North African Region – Diabetes Mortality (20-79 Years; Thousand), 2010
Table 7-14: South-East Asian Region – Population & Adult Population (Million), 2010 & 2030
Table 7-15: South-East Asian Region – Number of People with Diabetes & Comparative Prevalence (20-
     79 Years; Million, Percent), 2010 & 2030
Table 7-16: South-East Asian Region – Health Expenditure for Diabetes (Billion) & Type 1 Diabetes (0-14
     Years; Thousand), 2010 & 2030
Table 7-17: South-East Asian Region – Diabetes Mortality (20-79 Years; Thousand), 2010
Table 7-18: European Region – Population & Adult Population (Million), 2010 & 2030




© Renub Research                                Page 12 of 18
Table 7-19: European Region – Number of People with Diabetes & Comparative Prevalence (20-79
     Years; Million Percent), 2010 & 2030
Table 7-20: European Region – Number of People with IGT & Comparative Prevalence (20-79 Years;
     Million, Percent), 2010 & 2030
Table 7-21: European Region – Health Expenditure for Diabetes (Billion) & Type 1 Diabetes (0-14 Years;
     Thousand), 2010 & 2030
Table 7-22: European Region – Diabetes Mortality (20-79 Years; Thousand), 2010
Table 7-23: South and Central American Region – Population & Adult Population (Million), 2010 & 2030
Table 7-24: South and Central American Region – Number of People with Diabetes & Comparative
     Prevalence (20-79 Years; Million, Percent), 2010 & 2030
Table 7-25: South and Central American Region – Health Expenditure for Diabetes (Billion) & Type 1
     Diabetes (0-14 Years; Thousand), 2010 & 2030
Table 7-26: South and Central American Region – Diabetes Mortality (20-79 Years; Thousand), 2010
Table 7-27: Western Pacific Region – Population & Adult Population (Million), 2010 & 2030
Table 7-28: Western Pacific Region – Number of People with Diabetes & Comparative Prevalence (20-79
     Years; Million, Percent), 2010 & 2030
Table 7-29: Western Pacific Region – Health Expenditure for Diabetes (Billion) & Type 1 Diabetes (0-14
     Years; Thousand), 2010 & 2030
Table 7-30: Western Pacific Region – Diabetes Mortality (20-79 Years; Thousand), 2010
Table 7-31: African Region – Population & Adult Population (Million), 2010 & 2030
Table 7-32: African Region – Number of People with Diabetes & Comparative Prevalence (20-79 Years;
     Million, Percent), 2010 & 2030
Table 7-33: African Region – Number of People with IGT & Comparative Prevalence (20-79 Years;
     Million, Percent), 2010 & 2030
Table 7-34: African Region – Health Expenditure for Diabetes (Billion) & Type 1 Diabetes (0-14 Years;
     Thousand), 2010 & 2030
Table 7-35: African Region – Diabetes Mortality (20-79 Years; Thousand), 2010
Table 8-1: Global – Top 10 Countries Number of People with Diabetes (20-79 age group) (Million) 2010 &
     2030
Table 8-2: Global – Top 10 Countries in Prevalence of Diabetes (20-79 age group) (Percent), 2010 &
     2030
Table 8-3: India – Forecast for Number of People with Diabetes (Million), 2011 – 2030
Table 8-4: China – Forecast for Number of Diabetes Patients (Million), 2011 – 2030
Table 8-5: USA – Forecast for Number of Diabetes Patients (Million), 2011 – 2030
Table 8-6: Brazil – Forecast for Number of Diabetes Population (Million), 2011 – 2030
Table 8-7: Russia – Forecast for Number of Diabetes Population (Million), 2011 – 2030
Table 8-8: Mexico – Forecast for Number of Diabetes Patients (Million), 2011 – 2030



© Renub Research                              Page 13 of 18
Table 8-9: Indonesia – Forecast for Number of Diabetes Patients (Million), 2010 – 2030
Table 8-10: Pakistan – Forecast for Number of Diabetes Patients (Million), 2011 – 2030




© Renub Research                             Page 14 of 18
                                          Order Form

Scan and e-mail this page to info@renub.com, alternatively one can also write the Contact
Information in an e-mail and mail it. Else you can also fax this form to +91-120-424-9780


Questions? Please call +91-120-421-9822 (India), +1-678-302-0700 (USA) or mail to
info@renub.com


                                               Format

Report Title: Global Diabetes Market Trends & Future Forecast – Diabetes Drug (Anti-Diabetic
Drug), Insulin, DPP-IV, GLP-1


       Single User                Hard Copy                CD – Rom          Global Site License
  (Email from Publisher)        (Mail Delivery)          (Mail Delivery)   (Multiple User License)
        US$ 1,100                 US$ 1,250                   US$ 1,250          US$ 1,600



For ordering this report: Three easy ways to place your order:

1) Order online by Credit Card (Visa, MasterCard, etc.):
http://renub.com/reports/showdetails.aspx?id=27


2) Order by Wire Transfer:
http://renub.com/reports/wiretransfer.aspx?id=27&pid=1089


To pay by Wire Transfer, please, fill in your contact details in the form below:




© Renub Research                              Page 15 of 18
                                          Bank Details

Account Name: Renub Research
A/C No.: 109102000023296
Name of Bank: IDBI Bank Ltd.
Swift Code: IBKLINBB010
Bank Address: 4th Floor
              Indian Red Cross Building
              1 Red Cross Road
              Opposite Parliament Street
              New Delhi – 110001
              India




                                   Contact Information

First Name:                                  Last Name:
Email:
Job Title:
Company:
Address:
City:
Postal/Zip Code:
Country:
Phone:
Mobile:
Fax:
Report Format:
Your message:




© Renub Research                           Page 16 of 18
3) Order by Check


Please post the check accompanied by this form, to:


Company Address: Renub Research
                   A -116B
                   Sector -27
                   Noida - 201301
                   Uttar Pradesh
                   India
                   Phone: +91-120-4219-822, 4249-780




For free Sample copy report or to view any of our sample work please contact us at
info@renub.com or call +91-120-421-9822 (India), +1-678-302-0700 (USA)




                                        Follow Us


Facebook: http://www.facebook.com/pages/Renub-Research/233380966701090
LinkedIn: http://www.linkedin.com/company/renub-research




© Renub Research                         Page 17 of 18
About Us

Renub Research          is a leading Market Research and Information Analysis Company with
centers at Noida India and Roswell USA. We have more than 7 years of experience especially
in   international   Business-to-Business   Researches,     Surveys,   Business   and   Consulting.
Throughout the years we have acquired expertise in most market sectors, including
Information Technology (IT), Telecoms, Life Sciences, Medical & Pharmaceuticals, Financial
Services (Banking, Insurance, Reinsurance, M&A, etc.), Energy, Chemicals, Automotive,
Retail, FMCG, Consumer Goods, Logistics, Governmental, Social, and Others.


Our core team is comprised of an experienced people holding graduate, post graduate and
Ph.D. degrees in Finance, Marketing, Human Resource, Bio-Technology, Medicine, Information
Technology, Environmental Science and many more. Our research help make the business
decisions: on strategy, organization, operations, technology, mergers & acquisitions etc. We
support many blue chip companies by providing them findings and perspectives across a wide
range of markets. Our research reports offer a blend of information insight, analysis and
forecasting that is essential in today’s ultra-competitive markets.




© Renub Research                            Page 18 of 18

				
DOCUMENT INFO
Description: Report Details “Global Diabetes Market Trends & Future Forecast – Diabetes Drug (Anti-Diabetic Drug), Insulin, DPP-IV, GLP-1” report published by Renub Research provides an in-depth analysis of the past, present and future prospects. The report has been researched at source globally, country specific and features latest available data covering: • Global Diabetes Drug, Insulin, DPP-IV, GLP-1 Agonists Market and Future Forecast • Region wise Diabetes, Impaired Glucose Tolerance (IGT) Population and Prevalence • Region wise Diabetes Health Expenditure and Mortality • Top 10 Countries Diabetes Population and Future Forecast • Top 5 Countries Diabetes Drug Market and Future Forecast • Top 7 Countries Insulin Market and Future Forecast • Top 6 Diabetes Drug Brands ( Avandia, Actos, Amaryl, Avandamet, Prandin/Novonorm, Starlix) data of Past, Present and Future Market • Top 9 Insulin Brands (Novomix, Novorapid, Levemir, Degludec, Degludecplus, Humalog, Humulin, Apidra, Lantus) data of Past, Present and Future Market • Top 4 DPP-IV Inhibitors (Januvia, Onglyza, Alogliptin, Galvus) data of Past, Present and Future Market • Top 5 GLP-1 Agonists (Byetta, Victoza, Exenatide LAR, Syncria, Taspoglutide) data of Past, Present and Future Market Research Highlights • USA controls more than 50% of the total Diabetes Drug market share in 2009 • Global Insulin Market is estimated to reach around US$ 17 Billion by 2013 • China will have the second highest Insulin market share by 2012 replacing Germany • DPP-IV Inhibitors is predicted to be more than US$ 5 Billion market by 2015 • GLP-1 Agonists, market is forecasted to cross US$ 6 Billion mark by 2015 • Novorapid is the blockbuster Insulin of Novo Nordisk it is expected to cross US$ 3 Billion by 2015. • Yet to launched Degludec and DegludecPlus is expected to be blockbuster Insulin and cross US$ 4 Billion and US$ 6 Billion respectively by 2030. • Januvia is proving a blockbuster of DPP – IV Inhibitors